Bioassay to showcase new peptide services at CPhI Frankfurt

Heidelberg, Germany: – Specialist bioanalytical contract laboratory Bioassay GmbH will return to Europe’s largest pharma trade show, CPhI Worldwide, to exhibit an expanded portfolio of specific peptide synthesis and analysis services, sitting alongside its biopharma assays.

Bioassay’s acquisition of Heidelberg neighbor PSL Peptide Specialty Laboratories (PSL) at the beginning of the year has allowed it to constructed a highly integrated service portfolio of peptide synthesis, peptide specific antigen production, along with characterization of peptides and proteins, carried out in its analytical laboratories.

The Bioassay stand at Booth 40D32 at Messe Frankfurt will also present the company’s highly respected GMP analytical services, including its wide range of targeted potency, efficacy and safety assays.

High quality peptide production

“CPhI Europe is one of our favourite events,” commented Bioassay Chief Operating Officer Dr. Sven-Michael Cords.

“We have previously attended the fair when it was at Madrid and Paris and are looking forward to returning to Frankfurt as a great opportunity to reach out to our core user base of specialist researchers in biotech and biopharma companies who understand the value of high quality peptide production at a R&D level combined with functional analysis of these peptides,” Dr. Cords added.

About Bioassay

Bioassay GmbH is a German-based bioanalytical contract laboratory (CRO) specializing in the development, validation and routine performance of bioanalytical assays in the areas of Pharmacology and Toxicology. The company serves clients in the biotechnology, chemistry and cosmetics sectors and is particularly expert in carrying out potency assays under GMP for biopharmaceuticals, including therapeutic antibodies, hormones and cytokines.

Bioassay offers a range of services based on in-vivo and in-vitro systems including potency assays (GMP) and toxicity Studies (GLP) and has developed a range of proprietary customized, product specific, assays in accordance to ICH and FDA guidelines. Services focus on four key areas: Biopharma Potency, Biopharma Efficacy, Biopharma Safety and Chemicals / Cosmetics Safety.

Bioassay GmbH was privately founded in 2002 as a team of five people primarily focused on developing an Erythropoietin bioassay. Initially located at the BASF facilities in Ludwigshafen, Bioassay moved to its current location at Heidelberg’s Technology Park in 2005.

In early 2017, Bioassay acquired Heidelberg Technology Park neighbor PSL Peptide Specialty Laboratories GmbH (PSL), which specializes in customized peptide syntheses and peptide-specific antibodies.

About CPhI Worldwide 2017

CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitors networking opportunities with potential international pharmaceutical partners and collaborators, as well as latest industry insights.

Now in its 28th year, CPhI 2017 is a three-day event opening October 24 at the Messe Frankfurt exhibition center. Last year’s event in Barcelona attracted some 42,000 delegates and more than 2,500 exhibitor companies from 155 countries worldwide.

CPhI Worldwide is held alongside four other zoned exhibitions; ICSE Outsourcing solutions, P-MEC Machinery and Equipment, InnoPack pharmaceutical packaging and a new addition, the FDF show for Finished Dosage Formulations, bringing together every aspect of the dosage supply chain.

The CPhI Pharma Awards, presented on the first evening of the conference, honor innovative companies and leaders.

The CPhI series is staged by leading Global B2B Events Organizer and Publisher UBM Live More information at: www.cphi.com/europe/